Nanoparticle-NHE3 Peptide to Treat Diarrhea
Generated by an autonomous AI research agent — Anthropic Claude Opus 4.7 or OpenAI GPT-5.5, max reasoning effort. Sources cited inline. Full disclosure at /methodology/jhtv-deep-dive.
Indication
Severe diarrhea including in Crohn's disease, ulcerative colitis, and inflammatory bowel disease; nanoparticle-NHE3 peptide to enhance intestinal sodium absorption
Modality
Peptide
Mechanism
NHE3 activating peptide
Target
NHE3
rNPV Envelope
Low
-$44.5M
costs +25% · peak −25%
Base
-$31.4M
cumulative PoS 3.4%
High
-$18.4M
costs −25% · peak +25%
Costs follow a therapeutic-peptide profile with an elevated, elongated preclinical stage because the published work (Donowitz/Zachos, Gastroenterology 2023) explicitly has NOT solved oral delivery or gastric-acid stability and used PBAE-nanoparticle / cell-permeabilized delivery in mouse loops — a real CMC and route-of-administration program must precede IND. Phase 1 PoS uses gut-restricted-peptide tolerability precedent (tenapanor/teduglutide-class) but Phase 2 is held low because translating mouse cholera/ETEC/anti-CD3 loop data into a controlled human antisecretory endpoint is unproven and NHE3 is cytokine-downregulated in active IBD. Phase 3/NDA reflect orphan-GI peptide precedent (teduglutide) assuming the program narrows to a chronic, defined fluid-loss population rather than broad acute diarrhea.
Composite score breakdown
Locked rubric — 40/30/30 weights
Clinical relevance · 40%
0.65
Modality fit · 30%
0.31
Whitespace · 30%
1.00
Composite 0.654 — composite-score rank #13 of 50 top-tier inventions in the jhtv-portfolio@2026-Q2 cohort. The page header uses rNPV rank (#20) to match the index ordering.
Comparators
Real programs anchoring the engine inputs
Ibsrela / Xphozah (Ardelyx) — tenapanor
Same molecular target (NHE3) and same minimally-systemic GI-restricted design philosophy, but the exact mechanistic opposite: tenapanor INHIBITS NHE3 to retain luminal sodium/water and soften stool, whereas the JHU peptide STIMULATES NHE3 to absorb sodium/water and stop fluid loss. Tenapanor is the definitive proof that an NHE3-acting, gut-restricted agent is developable and commercially durable, and it directly anchors regulatory pathway, GI-restricted PK strategy, and the cost/duration of an NHE3-mechanism program. It is also a competitive-IP and mechanism-context anchor for the NHE3 target class.
Criteria 1 and 3: same target (NHE3) with an inverse mechanism; FDA-approved, gut-restricted NHE3 program anchoring regulatory pathway and 2024 combined U.S. net product sales (IBSRELA ~$158M + XPHOZAH ~$161M).
Mytesi / Fulyzaq (Jaguar Health / Napo) — crofelemer
Closest same-indication, same-therapeutic-goal precedent: the only FDA-approved first-in-class antisecretory antidiarrheal that, like this asset, blocks intestinal fluid loss without an antimotility mechanism (crofelemer modulates CFTR/CaCC chloride channels; the JHU peptide drives NHE3-mediated sodium/water absorption — different molecular handle, same net antisecretory clinical effect). CAUTIONARY commercial precedent, not a positive anchor: crofelemer was approved in 2012 for non-infectious HIV-associated diarrhea but commercialized poorly (gross sales ~$2.8M in 2017 against a ~$100M projected market), demonstrating that a mechanistically novel antisecretory antidiarrheal can clear FDA yet fail to find a reimbursed Western market in broad diarrhea.
Criteria 2: same indication space (secretory/antisecretory diarrhea) with a launched, mechanistically-novel antidiarrheal; included as the cautionary commercial ceiling for a novel-mechanism antidiarrheal in a poorly-reimbursed indication.
Gattex / Revestive (Takeda, orig. NPS Pharmaceuticals) — teduglutide
Modality- and economics-true archetype for the only commercially viable path this asset has: an injectable/parenterally-delivered peptide for a chronic, orphan GI fluid- and nutrient-malabsorption indication (short bowel syndrome). Teduglutide shows that a peptide that improves intestinal fluid/nutrient handling can build a durable orphan franchise (peak projections in the $350M+ range, acquired by Takeda via Shire) when targeted at a defined chronic high-unmet-need population rather than at broad acute diarrhea — the realistic commercial wedge for an NHE3-stimulating peptide.
Criteria 4 and 3: same modality (therapeutic peptide for intestinal fluid/nutrient balance) with comparable orphan patient-population economics and an established orphan GI regulatory/commercial pathway; anchors the realistic chronic-niche peak rather than the unfundable broad-diarrhea TAM.
Stage profile
Asset-specific cost, duration, and PoS by stage
| Stage | Cost | Duration | PoS | Citations |
|---|---|---|---|---|
| Preclinical | $20.0M | 30 mo | 40.0% | [0] [1] [5] |
| Phase I | $35.0M | 18 mo | 62.0% | [0] [2] |
| Phase II | $75.0M | 30 mo | 32.0% | [0] [3] [5] |
| Phase III | $180.0M | 36 mo | 52.0% | [3] [4] |
| NDA/BLA Review | $14.0M | 12 mo | 83.0% | [2] [4] |
Multiplier handling: Eligible multipliers (genetic_validation_2.6x, orphan_2.3x) are already reflected in Day-1 comparator-calibrated PoS. Re-applying them via log-odds stacking would double-count, so per-stage PoS is taken as final. See methodology for the rule.
Peak revenue and discount rate
$250.0M peak · WACC 13.0%
Peak revenue. The asset's own 'broad diarrhea, acute or chronic, all ages' positioning is not a fundable market: acute infectious/traveler's/cholera diarrhea is essentially unreimbursed in the West (global-health/ORS-displacement economics) and crofelemer proves a novel antisecretory antidiarrheal can be approved yet generate only single-digit-millions in broad diarrhea. The defensible peak is a chronic orphan GI fluid-loss niche modeled on teduglutide's orphan SBS franchise: ~$250M reflects a successful, narrowly-labeled chronic secretory/congenital-diarrhea peptide at orphan pricing, well below teduglutide's ~$700M because the addressable chronic population for an NHE3-stimulating antidiarrheal is narrower and the broad-diarrhea optionality is non-monetizable in reimbursed markets.
WACC. Preclinical peptide with strong human genetic target validation but an unsolved oral-delivery/CMC problem and a commercially treacherous indication (crofelemer precedent) sits above mainstream-GI risk (12%) but below high-risk CNS/cell therapy (14%).
Sensitivity (tornado)
Top drivers of rNPV variance
Drivers ranked by absolute rNPV swing. The vertical tick inside each bar marks the base rNPV (-$31.4M); each bar spans the rNPV range produced by flexing one input between its low and high values. Gold = the input pushes rNPV up when increased; red = the input pushes rNPV down when increased.
Monte Carlo distribution
1,000 trials · rpNPV mode
This is a bimodal distribution by construction, not a Gaussian. Most paths terminate in clinical failure (red cluster — accumulated cost only); a minority succeed and capture full peak revenue (green tail). Bar heights are square-root-scaled so the success tail stays visible alongside the much taller failure cluster; exact counts are preserved in the percentiles below. Gold line = median (P50). Navy dashed = base rNPV (mean) — the probability-weighted expected value, which can sit above the median when the upper tail is strong enough to outweigh the failure cluster (and close to the median when it isn’t).
P5
-$112.1M
P25
-$45.5M
P50 (median)
-$20.8M
P75
-$11.6M
P95
-$5.1M
Prob ≥ 0
3.9%
Comparable launch curves
Revenue trajectories of named comparators
Ibsrela / Xphozah (Ardelyx) — tenapanor
Launched 2019 · peak $304.0M (estimated)
Evidence register
8 per-assumption citations
| Assumption | Source | Date | Confidence |
|---|---|---|---|
Asset identity, mechanism, animal-model efficacy, and unsolved oral delivery stage_profile.preclinical.pos | A Novel Peptide Prevents Enterotoxin- and Inflammation-Induced Intestinal Fluid Secretion by Stimulating Sodium-Hydrogen Exchanger 3 Activity peer_review | 2023-07-08 | high |
Donowitz-lab Gastroenterology 2023 primary publication (peer-reviewed record) comparators[0] | A Novel Peptide Prevents Enterotoxin- and Inflammation-Induced Intestinal Fluid Secretion by Stimulating Sodium-Hydrogen Exchanger 3 Activity (PubMed record, PMID 37429363) peer_review | 2023-10-01 | high |
NHE3 (SLC9A3) human genetic validation — congenital sodium diarrhea multipliers_eligible | Sodium-hydrogen antiporter 3 (SLC9A3 / NHE3) — function and congenital sodium diarrhea peer_review | 2025-01-01 | medium |
Tenapanor — same-target NHE3 program, FDA approval, 2024 net sales comparators[0].peak_revenue_usd | Ardelyx Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update company_filing | 2025-02-20 | high |
Tenapanor gut-restricted minimally-systemic NHE3 safety/tolerability precedent stage_profile.phase_1.pos | Pharmacodynamics, Safety, and Tolerability of the NHE3 Inhibitor Tenapanor: Two Trials in Healthy Volunteers trial_disclosure | 2018-03-01 | high |
Crofelemer — novel antisecretory antidiarrheal regulatory + commercial precedent comparators[1] | Crofelemer (Mytesi/Fulyzaq) — mechanism, FDA approval, indication regulatory | 2025-01-01 | high |
Teduglutide — orphan GI fluid/nutrient peptide commercial archetype peak_revenue_usd | Gattex (Teduglutide) for Treatment of Short Bowel Syndrome (SBS) news | 2019-01-01 | medium |
Tenapanor IBS-C trial program anchoring NHE3-mechanism Ph2/Ph3 design and cost stage_profile.phase_3.cost_usd_m | Tenapanor (Ibsrela/Xphozah) — NHE3 inhibitor, Ardelyx, FDA approvals 2019/2023 regulatory | 2025-01-01 | high |
Thesis
Why this asset earns its rank
Johns Hopkins invention 52511 is a genuine therapeutic candidate, not a tool or discovery: a peptide (N3SP-1Δ7) that mimics the NHE3 C-terminus to stimulate the intestine's principal apical sodium absorber and reverse the cAMP/cGMP-driven shutdown that produces secretory diarrhea, delivered via carboxylated PBAE nanoparticles. The Donowitz/Zachos group's 2023 Gastroenterology paper is real, peer-reviewed, and shows ~42% reduction of cholera-toxin-induced fluid secretion in mouse loops plus efficacy against ETEC enterotoxin and anti-CD3 inflammation. The human genetics are strong — loss-of-function SLC9A3 causes congenital sodium diarrhea, so NHE3 demonstrably governs intestinal fluid balance. The decisive CMO problem is route of administration: the inventors explicitly state they have not pursued oral delivery and have not addressed gastric-acid stability, and the in vivo data used instilled/permeabilized delivery into mouse loops — for a luminal GI target the entire path to the apical enterocyte membrane in a swallowed product is unsolved, which is why preclinical is the dominant value-determining stage here.
The comparator economics reframe the asset away from its own 'broad diarrhea, all ages' positioning. Tenapanor (Ardelyx) is the same NHE3 target run in the opposite direction — an FDA-approved, gut-restricted franchise (~$319M combined 2024 U.S. net sales) that proves an NHE3-acting agent is developable and de-risks regulatory pathway and pivotal-trial design. Crofelemer (Mytesi) is the cautionary twin: the only approved first-in-class antisecretory antidiarrheal, it cleared FDA in 2012 yet generated only single-digit-millions in broad diarrhea, demonstrating that approval does not equal a reimbursed market for novel antidiarrheals. Teduglutide (Gattex/Revestive) shows the one viable wedge — an injectable peptide that builds a durable orphan franchise in a defined chronic GI fluid-loss population. The engine result is -$44.5M to -$18.4M, with a base rNPV of -$31.4M and cumulative PoS of 3.4%; that spread is consistent with a preclinical asset whose value is gated by an unsolved delivery problem and a market that only monetizes in an orphan chronic niche, not broad acute diarrhea.
Verdict: a scientifically credible, human-genetics-validated antisecretory peptide whose rubric rank is driven by clinical relevance in severe IBD/secretory diarrhea, a clean novel target, and high whitespace — but it is a partnership_candidate, not standalone VC-fundable, because the oral-delivery/CMC program is unsolved at preclinical, the strongest data are in infectious (developing-world) models rather than the pinned Crohn's indication, and the only reimbursable commercial path is a narrow orphan chronic-diarrhea niche modeled on teduglutide rather than the asset's stated broad-diarrhea TAM.
Key risks
Asset-specific, not generic biotech risks
- Route-of-administration is unsolved: the inventors explicitly have not pursued oral delivery or gastric-acid stability, and all in vivo efficacy used instilled/cell-permeabilized or nanoparticle delivery into surgically isolated mouse loops — translating an intracellularly-acting C-terminal-mimetic peptide to a stable, swallowed product that reaches the apical enterocyte membrane is a major, currently-unfunded CMC program and the single largest value risk.
- Indication framing oversells the data: the pinned indication is Crohn's/IBD but the strongest in vivo evidence is in infectious secretory diarrhea (cholera toxin, ETEC heat-stable enterotoxin) — developing-world / global-health models — with only anti-CD3 inflammation as an IBD-adjacent surrogate; NHE3 is cytokine-downregulated in active IBD mucosa, so whether an NHE3-stimulating peptide can overcome inflammatory NHE3 suppression in Crohn's patients is unproven.
- Commercial precedent is poor for the stated market: crofelemer, the only approved first-in-class antisecretory antidiarrheal, achieved only ~$2.8M gross sales (2017) against a ~$100M projected market; broad acute/infectious diarrhea is essentially unreimbursed in the West, so the asset is only monetizable if narrowed to an orphan chronic fluid-loss population (teduglutide archetype).
- On-target mechanistic ceiling: tenapanor demonstrates the NHE3 axis is dose-limited by its own GI fluid effects (NHE3 inhibition's principal adverse event is diarrhea); an NHE3 activator carries the symmetric risk of constipation/obstruction and a narrow therapeutic window that Phase 2 must define in humans.
- Funding-path risk: as a preclinical peptide with an unsolved delivery problem and a non-monetizable broad-diarrhea TAM, this needs a strategic/global-health partner (e.g., Gates/PATH-style for the cholera/ETEC use) or an orphan-GI developer rather than standalone biotech VC equity; standalone rNPV is negative at median WACC.